Bora Pharmaceuticals Co., LTD.

TWSE:6472 Rapport sur les actions

Capitalisation boursière : NT$80.2b

Bora Pharmaceuticals Croissance future

Future contrôle des critères 6/6

Bora Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 22.7% et de 23.7% par an respectivement. Le BPA devrait croître de de 22.7% par an. Le rendement des capitaux propres devrait être 27.5% dans 3 ans.

Informations clés

22.7%

Taux de croissance des bénéfices

22.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices58.7%
Taux de croissance des recettes23.7%
Rendement futur des capitaux propres27.5%
Couverture par les analystes

Good

Dernière mise à jour09 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem

Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects

Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt

Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality

Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Apr 30
Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Mar 17
Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?

Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

Feb 17
Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment

New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Jan 27
New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)

Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

Jan 19
Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt

We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Dec 29
We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings

Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Dec 09
Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?

Prévisions de croissance des bénéfices et des revenus

TWSE:6472 - Estimations futures des analystes et données financières antérieures (TWD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202629,123N/AN/AN/A1
12/31/202523,2224,9475,3376,1576
12/31/202418,6933,6692,9333,9525
9/30/202416,7053,9001,8142,366N/A
6/30/202414,1663,187-5751,011N/A
3/31/202412,2772,7072,3063,871N/A
12/31/202314,2003,0303,1834,614N/A
9/30/202316,2932,8682,8484,257N/A
6/30/202315,9422,7044,0384,362N/A
3/31/202314,1582,2523,6843,926N/A
12/31/202210,4941,3921,8102,010N/A
9/30/20226,3461,1281,3221,465N/A
6/30/20224,8116978441,029N/A
3/31/20224,6505941,0791,389N/A
12/31/20214,9007508731,237N/A
9/30/20214,4181,045636975N/A
6/30/20213,626963286603N/A
3/31/20212,794868-261-43N/A
12/31/20201,80057826178N/A
9/30/20201,523191-608188N/A
6/30/20201,513232-317415N/A
3/31/20201,521262-211478N/A
12/31/20191,529305-467232N/A
9/30/20191,517355373449N/A
6/30/20191,492283305373N/A
3/31/20191,515267262318N/A
12/31/20181,372443130167N/A
9/30/20181,107351-56-40N/A
6/30/2018846330N/A-218N/A
3/31/2018525274N/A-263N/A
12/31/201735814N/A20N/A
9/30/201732317N/A2N/A
6/30/201729722N/A22N/A
3/31/201729124N/A5N/A
12/31/201628325N/A-18N/A
9/30/201627323N/A-20N/A
6/30/201626018N/A-22N/A
3/31/201624726N/A-4N/A
12/31/201523834N/A9N/A
9/30/201523630N/A18N/A
6/30/201523428N/A13N/A
3/31/201522623N/A16N/A
12/31/201421817N/A18N/A
9/30/201418216N/A8N/A
6/30/201415416N/A0N/A
3/31/201412310N/A-11N/A
12/31/2013934N/A-21N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 6472 ( 22.7% par an) est supérieure au taux d'épargne ( 1.1% ).

Bénéfices vs marché: Les bénéfices de 6472 ( 22.7% par an) devraient croître plus rapidement que le marché TW ( 19.5% par an).

Croissance élevée des bénéfices: Les bénéfices de 6472 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 6472 ( 23.7% par an) devrait croître plus rapidement que le marché TW ( 12.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 6472 ( 23.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 6472 devrait être élevé dans 3 ans ( 27.5 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y